(PharmaNewsWire.Com, November 30, 2017 ) Hormone Therapy (HT) remains the most effective option to treat menopausal symptoms. There are many good clinical data to indicate that the use of HT started in early menopause is effective and safe. The Asia Pacific Hormone Replacement Therapy Market is estimated at USD 2.21 billion in 2016 and is predicted to reach USD 3.23 billion by 2021, growing at a CAGR of 7.92%.
Growing awareness on post-menopausal hazards, reimbursement policies, novel formulations, rise in unmet medical needs which require the employment of hormone therapy, benefits like lower risk of fractures are the few factors propelling the growth of Asia Pacific Hormone Replacement therapy market.
The major factor acting as a hurdle for market growth in the Asia-Pacific region is the cost of therapy. Normally, the therapy costs around $ 10,000. This is a pretty high amount considering the economic conditions of people in most of the countries in the Asia-Pacific region. Further, the risk of side effects, such as bloating, mood changes, and nausea, bleeding, breast tenderness or enlargement, headaches, risk of breast cancer, heart disease, and stroke is restraining the growth of the Asia-Pacific market. Along with this, women with high susceptibility to coronary diseases are kept away from taking hormone replacement therapy.
The Asia Pacific hormone replacement therapy market is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. The estrogen replacement therapy segment dominates the market, representing more than half of the market. While other therapies are still new in these regions and takes some time to get acquainted. Additionally, on the basis of route of administration the market is classified as oral, parenteral, transdermal and other routes. The oral route is regarded as one of the safest and most preferred routes of drug administration.
Further, on the basis of geography, the Asia Pacific Hormone Replacement therapy market is analysed under regions namely, India, China, Australia, Japan and South Korea. Japan holds the major share of the Asia Pacific Hormone Replacement therapy market while India & China are expected to register high growth rates during the forecast period.
Some of the key players operating in the Asia Pacific Hormone Replacement market are F. Hoffmann-La Roche, Novartis, Pfizer, Abbott Laboratories, Mylan Laboratories, Novo Nordisk, Amgen, Merck & Co., Bayer, Eli Lily, Wyeth and Hisamitsu Pharmaceutical Co. Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
